HNGE vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HNGE presents a stark contrast between operational growth and financial health, anchored by a weak Piotroski F-Score of 2/9. While the company exhibits strong top-line revenue growth (45.6%) and impressive gross margins (79.83%), it suffers from severe net profitability issues and a highly inflated Price-to-Book ratio of 19.95. The bullish analyst consensus is heavily contradicted by aggressive insider selling totaling $35.15M. Overall, the company is in a high-growth phase but lacks the fundamental stability required for a bullish rating.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HNGE vs LLY: Head-to-Head Comparison
This page compares Hinge Health, Inc. (HNGE) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.